A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study

Inclusion Criteria:

• is considered to be "clinically possible" or "clinically probable" MSA as determinedby the Gilman criteria

• is able to ambulate at least 10 meters without the assistance of another person atscreening; the use of assistive device (eg, cane, not walker) is allowed

• is medically and psychiatrically stable, as indicated by medical and psychiatrichistory, as well as physical and neurological examination

• Females of child bearing potential (CBP) may be included only if they have anegative pregnancy test at the screening and baseline visits

• Females of CBP whose male partners are potentially fertile (ie, no vasectomy) mustuse highly effective birth control methods

• Males who are potentially fertile/reproductively competent (not surgically [eg,vasectomy] or congenitally sterile) and their female partners who are of CBP mustuse, together with their female partners, highly effective birth control methods

• Additional criteria apply; please contact the investigator for more information

Exclusion Criteria:

• has 2 or more relatives with history of MSA, suggestive of an alternative diagnosisother than MSA

• has participated in another clinical study involving administration of an IMP within 3 months or 5 half-lives (whichever is longer) of this IMP prior to screening

• has a history of, or acknowledges, alcohol or other substance abuse in the 12 monthsbefore screening

• is a female participant who is pregnant or breastfeeding, or plans to becomepregnant during the study

• has a known hypersensitivity to any components of the IMP

• is of a vulnerable population (eg, people kept in detention or jail)

• participant is using or consuming any prohibited concomitant medications within thespecified exclusionary windows of this study

• Additional criteria apply; please contact the investigator for more information